-
Early Keytruda Results Win Merck An Upgrade
Tuesday, January 16, 2018 - 2:19pm | 345Read More...Merck & Co., Inc. (NYSE: MRK) announced encouraging data Tuesday from a key study of patients with lung cancer. The combination of Merck's blockbuster drug Keytruda and two chemotherapy medicines helped patients live longer and played a role in stopping the disease from advancing...
-
SunTrust Cuts Target On Bristol-Myers As Opdivo Estimates Revised Lower
Monday, October 10, 2016 - 10:08am | 351Read More...After Bristol-Myers Squibb Co (NYSE: BMY) disclosed disappointing study results of its Opdivo, SunTrust has reduced the price target on the company's shares from $68 to $62 on lower EPS estimates for the year 2017 and 2018. However, the firm maintains its Hold rating on the stock. Analyst John...
-
SunTrust On Jazz's Celator Purchase: 'Makes Strategic, Financial Sense'
Thursday, June 2, 2016 - 3:04pm | 240Read More...SunTrust said Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ: JAZZ)'s $1.5 billion/$30.25 a share acquisition of Celator Pharmaceuticals Inc (NASDAQ: CPXX) makes "strategic & financial sense." "Strategically, it leverages Jazz's Hem/Onc infrastructure by adding...
-
SunTrust's Latest Comments On Merck
Wednesday, April 15, 2015 - 3:32pm | 285Read More...In a report published Tuesday, SunTrust Robinson Humphrey analyst John Boris discussed the FDA AdCom's vote to add safety warnings to AstraZeneca plc (NYSE: AZN)'s Onglyza and Takeda's Nesina, which is a positive for Merck & Co., Inc. (NYSE: MRK)'s Januvia franchise. The FDA AdCom voted that...
-
SunTrust Sees Further Pfizer Inc. Bid For AstraZeneca PLC (ADR) 'Highly Likely'
Tuesday, September 2, 2014 - 3:35pm | 195Read More...Pfizer Inc. (NYSE: PFE) is likely to boost its offer for British drug maker AstraZeneca PLC (ADR) (NYSE: AZN) to $96.28 a share, an analyst said Tuesday. SunTrust's John Boris said a deal would cut Pfizer's tax rate to 20 percent and said potential Treasury inversion action blocking...
-
Shire Shares Trend Higher On SunTrust's Note Of Possible Allergan Bid
Wednesday, June 18, 2014 - 8:56am | 193Read More...Shares of Shire plc (NASDAQ: SHPG) jumped 2.2 percent in Wednesday's pre-market following a SunTrust note suggesting that Allergan could bid for the pharmaceutical company. SunTrust analyst John T. Boris reported that Allergan's bid for Shire would be “more attractive” than Valeant's proposal. The...
-
Citi Rates Mylan (MYL) A High Risk Buy
Tuesday, June 8, 2010 - 10:04am | 225Read More...Citi Investment Research & Analysis analysts John Boris, Morten Marott, Timothy W Chou and Nirav Jhaveri maintained their Buy/High Risk rating for shares of Mylan Inc (Nasdaq: MYL), with a price target of $23 per share. The analysts said that Mylan Inc is currently trading near the bottom of...
-
Citi Sees EPS Growth For Teva Pharmaceutical Industries (TEVA)
Friday, May 28, 2010 - 11:57am | 227Read More...Citi Investment Research & Analysis analysts John Boris, Morten Marott, Timothy W Chou and Nirav Jhaveri rated shares of Teva Pharmaceutical Industries (Nasdaq: TEVA) a Buy, with a price target of $72 per share. The analysts noted that Teva Pharmaceutical Industries recently reiterated that its...
-
Citi Says Mylan (MYL) Shares Are A Buy
Friday, May 28, 2010 - 11:29am | 187Read More...Citi Investment Research & Analysis analysts John Boris, Morten Marott, Timothy W Chou and Nirav Jhaveri rated shares of Mylan Inc (Nasdaq: MYL) a Buy, with a target price of $23 per share. The analysts said that the management of Mylan Inc said that pricing pressure on European generic drugs...
-
Citi Sees Strong Upside At Watson Pharmaceuticals (WPI)
Friday, May 28, 2010 - 11:10am | 197Read More...Citi Investment Research & Analysis analysts John Boris, Morten Marott, Timothy W Chou and Nirav Jhaveri rated shares of Watson Pharmaceuticals Inc (NYSE: WPI) a Buy, with a price target of $48 per share. The analysts said that they still expect to see a strong 2011 from Watson Pharmaceuticals...
-
Citigroup Rates Teva Pharmaceutical Industries (TEVA) A Buy After Court Ruling
Thursday, April 1, 2010 - 4:24pm | 195Read More...Citigroup Global Markets analyst John Boris reiterated his Buy rating for shares of Teva Pharmaceutical Industries (Nasdaq: TEVA), with a price target of $72. Boris reiterated his Buy rating after an Indiana Southern District Court (INSDC) ruled in favor of Eli Lilly and Company (NYSE: LLY) in one...
-
Drug Pipeline Targeting High Growth Markets May Boost Merck Prospects (MRK, C)
Tuesday, January 5, 2010 - 9:30am | 93Read More...John Boris, an analyst at Citigroup (NYSE: C) has increased the price target of pharma major Merck (NYSE: MRK) from $38 to $45. The scrip has been rated as Buy/Medium Risk. The analyst believes that Merck is more diversified with larger exposure to non U.S. markets. Merck’s pipeline in high growth...
